Role of adenosine in diabetic retinopathy

Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41(7):1971–80.

Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17(3):463–71.

Ammary-Risch NJ, Huang SS. The primary care physician's role in preventing vision loss and blindness in patients with diabetes. J Natl Med Assoc. 2011;103(3):281–3.

Bursell SE, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37(5):886–97.

Benson WE, et al. Current popularity of pneumatic retinopexy. Retina. 1999;19(3):238–41.

Palmberg PF. Diabetic retinopathy. Diabetes. 1977;26(7):703–9.

Joussen AM, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450–2.

Barber AJ, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102(4):783–91.

El-Remessy AB, et al. Experimental diabetes causes breakdown of the blood–retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol. 2003;162(6):1995–2004.

El-Remessy AB, et al. Neuroprotective and blood–retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168(1):235–44.

Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.

Ali TK, et al. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes. 2008;57(4):889–98.

Langmann T. Microglia activation in retinal degeneration. J Leukoc Biol. 2007;81(6):1345–51.

El-Remessy AB, et al. Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. Mol Vis. 2010;16:1487–95.

Ambati J, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115(9):1161–6.

Lieth E, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 1998;47(5):815–20.

Kowluru RA, et al. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int. 2001;38(5):385–90.

Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262(5134):689–95.

Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312–8.

Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9(4):315–27.

Aloisi F. Immune function of microglia. Glia. 2001;36(2):165–79.

Wood PL. Neuroinflammation: mechanisms and management. Totowa New York, NY: Humana Press; 2003.

Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227–32.

Yang LP, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(5):2319–27.

Liu W, et al. Expression of macrophage colony-stimulating factor (M-CSF) and its receptor in streptozotocin-induced diabetic rats. Curr Eye Res. 2009;34(2):123–33.

Ibrahim AS, et al. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis. 2010;16:2033–42.

Joussen AM, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418–28.

Joussen AM, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16(3):438–40.

Ibrahim AS, et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes. 2011;60(4):1122–33.

Schalkwijk CG, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42(3):351–7.

Tang J, et al. Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia. 2000;43(11):1417–23.

Wang AL, et al. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp Eye Res. 2007;84(5):905–13.

Schalkwijk CG. Comment on “AGEs mediated expression and secretion of TNF alpha in rat retinal microglia” by Dr Wang et al. Exp Eye Res. 2007;85:572–3. doi:4. author reply 574.

Quan Y, Du J, Wang X. High glucose stimulates GRO secretion from rat microglia via ROS, PKC, and NF-kappaB pathways. J Neurosci Res. 2007;85(14):3150–9.

Collis MG, Hourani SM. Adenosine receptor subtypes. Trends Pharmacol Sci. 1993;14(10):360–6.

Fredholm BB, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994;46(2):143–56.

Feoktistov I, Goldstein AE, Biaggioni I. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol Pharmacol. 1999;55(4):726–34.

Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-d-aspartate receptors. J Clin Invest. 1996;98(12):2779–85.

Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50(3):413–92.

Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414(6866):916–20.

Awad AS, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290(4):F828–37.

Liou GI, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci. 2008;49(12):5526–31.

Ibrahim AS, et al. A(2A) adenosine receptor (A(2A)AR) as a therapeutic target in diabetic retinopathy. Am J Pathol. 2011;178(5):2136–45.

Williams M. Challenges in developing P2 purinoceptor-based therapeutics. CIBA Found Symp. 1996;198:309–21.

Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;256(4 Pt 1):C799–806.

Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A. 2006;103(20):7895–900.

Dunwiddie TV, Diao L. Regulation of extracellular adenosine in rat hippocampal slices is temperature dependent: role of adenosine transporters. Neuroscience. 2000;95(1):81–8.

Picano E, Michelassi C. Chronic oral dipyridamole as a ‘novel’ antianginal drug: the collateral hypothesis. Cardiovasc Res. 1997;33(3):666–70.

De la Cruz JP, et al. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther. 1997;280(1):454–9.

Leung GP, Man RY, Tse CM. D-Glucose upregulates adenosine transport in cultured human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005;288(6):H2756–62.

Pawelczyk T, Podgorska M, Sakowicz M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol Pharmacol. 2003;63(1):81–8.

Buckley NE, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396(2–3):141–9.

Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S–9S.

Malfait AM, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561–6.

El-Remessy AB, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis. 2008;14:2190–203.

Braida D, et al. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett. 2003;346(1–2):61–4.

Rajesh M, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol. 2007;293(1):H610–9.

Weiss L, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity. 2006;39(2):143–51.

Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006;7(5):607–15.

Liou G, et al. Cannabidiol as a putative novel therapy for diabetic retinopathy: a postulated mechanism of action as an entry point for biomarker-guided clinical development. Curr Pharmacogenomics Person Med. 2009;7(3):215–22.